ArticleBMC cancer2013
Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics.
Article in BMC cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- In Vivo ORF Overexpression Screening Identifies CCN4 as a Regulator of Glioblastoma Growth Validated Across Multiple Models.International journal of molecular sciences · 2026Article
- Transposon mediated functional genomic screening for BRAF inhibitor resistance reveals convergent Hippo and MAPK pathway activation events.Scientific reports · 2025Article
- LITAF protects against pore-forming protein-induced cell death by promoting membrane repair.Science immunology · 2024Article
- Zebrafish models of acute leukemias: Current models and future directions.Wiley interdisciplinary reviews. Developmental biology · 2021Review
- A CRISPR cut for messenger RNAs.Lab animal · 2020Article
- MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses.Science (New York, N.Y.) · 2020Article
- Genome-wide Screen for Culture Adaptation and Tumorigenicity-Related Genes in Human Pluripotent Stem Cells.iScience · 2019Article
- Article
- CRISPR/Cas9 library screening for drug target discovery.Journal of human genetics · 2018Review
- Downregulation of cytochromeOncology letters · 2017Article
- Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an ArfProceedings of the National Academy of Sciences of the United States of America · 2017Article
- Article
- The utility of transposon mutagenesis for cancer studies in the era of genome editing.Genome biology · 2015Review
- Comprehensive screening of genes resistant to an anticancer drug in esophageal squamous cell carcinoma.International journal of oncology · 2015Article
- Review
- Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Mutagenesis and phenotyping resources in zebrafish for studying development and human disease.Briefings in functional genomics · 2014Review
- Protein kinase A type II-α regulatory subunit regulates the response of prostate cancer cells to taxane treatment.Cell cycle (Georgetown, Tex.) · 2014Article
- A nucleolus-predominant piggyBac transposase, NP-mPB, mediates elevated transposition efficiency in mammalian cells.PloS one · 2014Article
- Novel dimensions of piRNAs in cancer.Cancer letters · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe development of resistance to chemotherapies represents a significant barrier to successful cancer treatment. Resistance mechanisms are complex, can involve diverse and often unexpected cellular processes, and can vary with both the underlying genetic lesion and the origin or type of tumor. For these reasons developing experimental strategies that could be used to understand, identify and predict mechanisms of resistance in different malignant cells would be a major advance.
methodsHere we describe a gain-of-function forward genetic approach for identifying mechanisms of resistance. This approach uses a modified piggyBac transposon to generate libraries of mutagenized cells, each containing transposon insertions that randomly activate nearby gene expression. Genes of interest are identified using next-gen high-throughput sequencing and barcode multiplexing is used to reduce experimental cost.
resultsUsing this approach we successfully identify genes involved in paclitaxel resistance in a variety of cancer cell lines, including the multidrug transporter ABCB1, a previously identified major paclitaxel resistance gene. Analysis of co-occurring transposons integration sites in single cell clone allows for the identification of genes that might act cooperatively to produce drug resistance a level of information not accessible using RNAi or ORF expression screening approaches.
conclusionWe have developed a powerful pipeline to systematically discover drug resistance in mammalian cells in vitro. This cost-effective approach can be readily applied to different cell lines, to identify canonical or context specific resistance mechanisms. Its ability to probe complex genetic context and non-coding genomic elements as well as cooperative resistance events makes it a good complement to RNAi or ORF expression based screens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.